Scott B Halstead

List of Publications by Year
in descending order

144 papers	14,603 citations	23567 58 h-index	20358 116 g-index
281 all docs	281 docs citations	281 times ranked	9697 citing authors

#	Article	IF	Citations
1	Dengue: a continuing global threat. Nature Reviews Microbiology, 2010, 8, S7-S16.	28.6	1,506
2	Dengue. Lancet, The, 2007, 370, 1644-1652.	13.7	1,236
3	RISK FACTORS IN DENGUE SHOCK SYNDROME: A PROSPECTIVE EPIDEMIOLOGIC STUDY IN RAYONG, THAILAND. American Journal of Epidemiology, 1984, 120, 653-669.	3.4	627
4	Neutralization and Antibody-Dependent Enhancement of Dengue Viruses. Advances in Virus Research, 2003, 60, 421-467.	2.1	617
5	Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Archives of Virology, 2013, 158, 1445-1459.	2.1	546
6	Dengue infection. Nature Reviews Disease Primers, 2016, 2, 16055.	30.5	415
7	Dengue Virusâ€“Mosquito Interactions. Annual Review of Entomology, 2008, 53, 273-291.	11.8	345
8	Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infectious Diseases, The, 2010, 10, 712-722.	9.1	334
9	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962â€“1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 954-971.	1.4	303
10	Effect of age on outcome of secondary dengue 2 infections. International Journal of Infectious Diseases, 2002, 6, 118-124.	3.3	262
11	Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet, The, 1999, 354, 1431-1434.	13.7	260
12	Rubella: Reinfection of Vaccinated and Naturally Immune Persons Exposed in an Epidemic. New England Journal of Medicine, 1970, 283, 771-778.	27.0	250
13	Original Antigenic Sin in Dengue. American Journal of Tropical Medicine and Hygiene, 1983, 32, 154-156.	1.4	244
14	Dengue Hemorrhagic Fever in Infants: A Study of Clinical and Cytokine Profiles. Journal of Infectious Diseases, 2004, 189, 221-232.	4.0	233
15	Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiology Spectrum, 2014, 2, .	3.0	225
16	Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored. Emerging Infectious Diseases, 2002, 8, 1474-1479.	4.3	216
17	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962â€“1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 997-1021.	1.4	196
18	Evaluation of Commercially Available Antiâ€“Dengue Virus Immunoglobulin M Tests. Emerging Infectious Diseases, 2009, 15, 436-440.	4.3	188

#	Article	IF	Citations
19	In-Depth Analysis of the Antibody Response of Individuals Exposed to Primary Dengue Virus Infection. PLoS Neglected Tropical Diseases, 2011, 5, e1188.	3.0	184
20	Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2002, 11, 223-227.	1.1	174
21	Studies on the Pathogenesis of Dengue Infection in Monkeys. II. Clinical Laboratory Responses to Heterologous Infection. Journal of Infectious Diseases, 1973, 128, 15-22.	4.0	170
22	Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age. Vaccine, 2017, 35, 6355-6358.	3.8	159
23	Efficacy of single-dose SA 14â€“14â€“2 vaccine against Japanese encephalitis: a case control study. Lancet, The, 2001, 358, 791-795.	13.7	154
24	Natural History of Dengue Virus (DENV)â€“1 and DENVâ€4 Infections: Reanalysis of Classic Studies. Journal of Infectious Diseases, 2007, 195, 1007-1013.	4.0	149
25	Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet, The, 2002, 360, 310-312.	13.7	148
26	The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries. PLoS Neglected Tropical Diseases, 2016, 10, e0005179.	3.0	146
27	Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine, 2016, 34, 1643-1647.	3.8	143
28	Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar. Human Pathology, 2014, 45, 1221-1233.	2.0	136
29	Enhancement of Dengue Virus Infection in Monocytes by Flavivirus Antisera *. American Journal of Tropical Medicine and Hygiene, 1980, 29, 638-642.	1.4	134
30	How Innate Immune Mechanisms Contribute to Antibody-Enhanced Viral Infections. Vaccine Journal, 2010, 17, 1829-1835.	3.1	127
31	Cost-effectiveness of a pediatric dengue vaccine. Vaccine, 2004, 22, 1275-1280.	3.8	125
32	Dengue. Current Opinion in Infectious Diseases, 2002, 15, 471-476.	3.1	124
33	The future of dengue vaccines. Lancet, The, 2002, 360, 1243-1245.	13.7	123
34	Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: A caseâ€“control study in Nepalese children 5 years after immunization. Vaccine, 2007, 25, 5041-5045.	3.8	115
35	New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Review of Vaccines, 2011, 10, 355-364.	4.4	115
36	DENGUE HEMORRHAGIC FEVER CAUSED BY SEQUENTIAL DENGUE 1â€“3 VIRUS INFECTIONS OVER A LONG TIME INTERVAL: HAVANA EPIDEMIC, 2001â€“2002. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1113-1117.	1.4	114

#	Article	IF	Citations
37	Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet, The, 2005, 366, 1375-1378.	13.7	109
38	Dengue vaccine development: a 75% solution?. Lancet, The, 2012, 380, 1535-1536.	13.7	105
39	Neutralizing Antibodies after Infection with Dengue 1 Virus. Emerging Infectious Diseases, 2007, 13, 282-286.	4.3	99
40	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962â€“1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 972-983.	1.4	97
41	Identifying protective dengue vaccines: Guide to mastering an empirical process. Vaccine, 2013, 31, 4501-4507.	3.8	96
42	Shock associated with dengue infection. Journal of Pediatrics, 1966, 68, 448-456.	1.8	93
43	High-Avidity and Potently Neutralizing Cross-Reactive Human Monoclonal Antibodies Derived from Secondary Dengue Virus Infection. Journal of Virology, 2013, 87, 12562-12575.	3.4	92
44	The risks behind Dengvaxia recommendation. Lancet Infectious Diseases, The, 2016, 16, 882-883.	9.1	92
45	Etiologies of the Experimental Dengues of Siler and Simmons *. American Journal of Tropical Medicine and Hygiene, 1974, 23, 974-982.	1.4	92
46	Severe dengue in travellers: pathogenesis, risk and clinical management. Journal of Travel Medicine, 2019, 26, .	3.0	86
47	Japanese Encephalitis: New Options for Active Immunization. Clinical Infectious Diseases, 2010, 50, 1155-1164.	5.8	84
48	Immune correlates of protection for dengue: State of the art and research agenda. Vaccine, 2017, 35, 4659-4669.	3.8	81
49	ASSOCIATION BETWEEN SEX, NUTRITIONAL STATUS, SEVERITY OF DENGUE HEMORRHAGIC FEVER, AND IMMUNE STATUS IN INFANTS WITH DENGUE HEMORRHAGIC FEVER. American Journal of Tropical Medicine and Hygiene, 2005, 72, 370-374.	1.4	81
50	Immunological Parameters of Togavirus Disease Syndromes. , 1980, , 107-173.		78
51	Controlling Dengue with Vaccines in Thailand. PLoS Neglected Tropical Diseases, 2012, 6, e1876.	3.0	74
52	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962â€“1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 984-996.	1.4	72
53	Do escape mutants explain rapid increases in dengue casefatality rates within epidemics?. Lancet, The, 2000, 355, 1902-1903.	13.7	71
54	Dengue Hemorrhagic Fever at 60 Years: Early Evolution of Concepts of Causation and Treatment. Microbiology and Molecular Biology Reviews, 2015, 79, 281-291.	6.6	69

#	Article	IF	Citations
55	Antibodies Determine Virulence in Dengue. Annals of the New York Academy of Sciences, 2009, 1171, E48-56.	3.8	67
56	Controversies in dengue pathogenesis. Paediatrics and International Child Health, 2012, 32, 5-9.	1.0	67
57	Dengue Virus Replication Enhancement in Peripheral Blood Leukocytes from Immune Human Beings. Experimental Biology and Medicine, 1976, 151, 136-139.	2.4	63
58	Pathogenesis of Dengue: Dawn of a New Era. F1000Research, 2015, 4, 1353.	1.6	63
59	Recent advances in understanding dengue. F1000Research, 2019, 8, 1279.	1.6	63
60	Japanese encephalitis vaccines. , 2008, , 311-352.		62
61	BIOLOGIC PROPERTIES OF DENGUE VIRUSES FOLLOWING SERIAL PASSAGE IN PRIMARY DOG KIDNEY CELLS: STUDIES AT THE UNIVERSITY OF HAWAII. American Journal of Tropical Medicine and Hygiene, 2003, 69, 5-11.	1.4	62
62	The burden of dengue infection. Lancet, The, 2007, 369, 1410-1411.	13.7	61
63	Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. Human Vaccines and Immunotherapeutics, 2018, 14, 2158-2162.	3.3	55
64	COVID-19 Vaccines: Should We Fear ADE?. Journal of Infectious Diseases, 2020, 222, 1946-1950.	4.0	55
65	Dengue and Chikungunya Virus Infection in Man in Thailand, 1962â€“1964. American Journal of Tropical Medicine and Hygiene, 1969, 18, 1022-1033.	1.4	55
66	STUDIES ON THE IMMUNIZATION OF MONKEYS AGAINST DENGUE. American Journal of Tropical Medicine and Hygiene, 1973, 22, 365-374.	1.4	53
67	Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1113-7.	1.4	53
68	Critique of World Health Organization Recommendation of a Dengue Vaccine. Journal of Infectious Diseases, 2016, 214, 1793-1795.	4.0	52
69	Transmission of Dengue 1 and 2 Viruses in Greece in 1928 *. American Journal of Tropical Medicine and Hygiene, 1980, 29, 635-637.	1.4	51
70	Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies. Emerging Infectious Diseases, 2017, 23, 569-573.	4.3	50
71	Recent Epidemics of Hemorrhagic Fever in Thailand: Observations Related to Pathogenesis of a â€œNewâ€• Dengue Disease. American Journal of Public Health and the Nation's Health, 1965, 55, 1386-1395.	0.3	45
72	More Dengue, More Questions. Emerging Infectious Diseases, 2005, 11, 740-741.	4.3	45

#	Article	IF	Citations
73	Ethics of a partially effective dengue vaccine: Lessons from the Philippines. Vaccine, 2020, 38, 5572-5576.	3.8	43
74	An explanation for enhanced virus plaque formation in chick embryo cells. Nature, 1980, 285, 504-505.	27.8	41
75	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1329-1339.	4.7	40
76	Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. American Journal of Tropical Medicine and Hygiene, 2016, 95, 741-745.	1.4	39
77	Comparison of P388D1 Mouse Macrophage Cell Line and Human Monocytes for Assay of Dengue-2 Infection-Enhancing Antibodies. American Journal of Tropical Medicine and Hygiene, 1983, 32, 157-163.	1.4	39
78	Recombination and flavivirus vaccines: a commentary. Vaccine, 2005, 23, 2956-2958.	3.8	37
79	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a030700.	5.5	37
80	Consider stopping dengvaxia administration without immunological screening. Expert Review of Vaccines, 2017, 16, 301-302.	4.4	36
81	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1340-1351.	4.7	35
82	VOLUME REPLACEMENT IN INFANTS WITH DENGUE HEMORRHAGIC FEVER/DENGUE SHOCK SYNDROME. American Journal of Tropical Medicine and Hygiene, 2006, 74, 684-691.	1.4	34
83	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1362-1368.	4.7	33
84	A T164S mutation in the dengue virus NS1 protein is associated with greater disease severity in mice. Science Translational Medicine, 2019, 11, .	12.4	32
85	Studies of hemostasis in Thai hemorrhagic fever. Journal of Pediatrics, 1965, 66, 918-926.	1.8	31
86	Assessing the Potential of a Candidate Dengue Vaccine with Mathematical Modeling. PLoS Neglected Tropical Diseases, 2012, 6, e1450.	3.0	31
87	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1320-1328.	4.7	30
88	Dengue: The Syndromic Basis to Pathogenesis Research. Inutility of the 2009 WHO Case Definition. American Journal of Tropical Medicine and Hygiene, 2013, 88, 212-215.	1.4	30
89	Epidemiological studies on dengue virus type 3 in Playa municipality, Havana, Cuba, 2001â€“2002. International Journal of Infectious Diseases, 2012, 16, e198-e203.	3.3	29
90	Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue. Lancet Infectious Diseases, The, 2017, 17, e378-e382.	9.1	29

#	Article	IF	Citations
91	Dengue infection and advances in dengue vaccines for children. The Lancet Child and Adolescent Health, 2019, 3, 734-741.	5.6	29
92	A relevant in vitro human model for the study of Zika virus antibody-dependent enhancement. Journal of General Virology, 2017, 98, 1702-1712.	2.9	29
93	Virus Role During Intraepidemic Increase in Dengue Disease Severity. Vector-Borne and Zoonotic Diseases, 2011, 11, 675-681.	1.5	28
94	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 679-683.	1.4	28
95	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1352-1361.	4.7	27
96	Studies of Bladder Stone Disease in Thailand. American Journal of Clinical Nutrition, 1967, 20, 1312-1319.	4.7	25
97	Call to Action for Dengue Vaccine Failure. Emerging Infectious Diseases, 2013, 19, 1335-1337.	4.3	25
98	Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. , 0, , 249-271.		25
99	Dengueâ€"The Case Definition Dilemma: A Commentary. Pediatric Infectious Disease Journal, 2007, 26, 291-292.	2.0	23
100	Dengue 1 Virus and Dengue Hemorrhagic Fever, French Polynesia, 2001. Emerging Infectious Diseases, 2009, 15, 1265-1270.	4.3	23
101	Dengue Vascular Permeability Syndrome: What, No T Cells?. Clinical Infectious Diseases, 2013, 56, 900-901.	5.8	23
102	Use of the live attenuated Japanese Encephalitis vaccine SA 14â€“14â€“2 in children: A review of safety and tolerability studies. Human Vaccines and Immunotherapeutics, 2017, 13, 2222-2231.	3.3	23
103	Is Dengvaxia a useful vaccine for dengue endemic areas?. BMJ: British Medical Journal, 2019, 367, l5710.	2.3	23
104	New Vaccines for Japanese Encephalitis. Current Infectious Disease Reports, 2010, 12, 174-180.	3.0	19
105	Japanese encephalitis vaccines. , 2013, , 312-351.		19
106	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 672-678.	1.4	19
107	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 654-665.	1.4	18
108	Dengue vaccines: Are they safe for travelers?. Travel Medicine and Infectious Disease, 2016, 14, 378-383.	3.0	17

#	Article	IF	Citations
109	In vitro Recovery of Dengue Viruses from Naturally Infected Human Beings and Arthropods. Nature, 1964, 202, 931-932.	27.8	16
110	Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines. PLoS Neglected Tropical Diseases, 2016, 10, e0004854.	3.0	16
111	Epidemiology of bladder stone of children: precipitating events. Urolithiasis, 2016, 44, 101-108.	2.0	16
112	Japanese encephalitis vaccine for travelers: risk-benefit reconsidered. Journal of Travel Medicine, 2019, 26, .	3.0	16
113	Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development. BioDrugs, 2021, 35, 505-515.	4.6	16
114	Assessing the prognosis of dengue-infected patients. F1000 Medicine Reports, 2009, 1, .	2.9	16
115	Travelling arboviruses: A historical perspective. Travel Medicine and Infectious Disease, 2019, 31, 101471.	3.0	14
116	Absence of Dengue 2 Infection Enhancement in Human Sera Containing Japanese Encephalitis Antibodies. American Journal of Tropical Medicine and Hygiene, 1984, 33, 288-294.	1.4	14
117	Insights from direct studies on human dengue infections. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17-19.	7.1	13
118	Selection of Attenuated Dengue 4 Viruses by Serial Passage in Primary Kidney Cells. American Journal of Tropical Medicine and Hygiene, 1984, 33, 666-671.	1.4	12
119	Dengue Vaccine Efficacy: Not a Zero Sum Game. Journal of Infectious Diseases, 2016, 214, 2014-2014.	4.0	11
120	Zika enhancement: a reality check. Lancet Infectious Diseases, The, 2017, 17, 686-688.	9.1	11
121	Pathogenesis: Risk Factors Prior to Infection. Tropical Medicine, 2008, , 219-256.	0.3	10
122	COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase. Frontiers in Immunology, 2020, 11, 1196.	4.8	10
123	Japanese Encephalitis Vaccines. , 2018, , 511-548.e12.		8
124	Is Dengue Vaccine Protection Possible?. Clinical Infectious Diseases, 2022, 74, 156-160.	5.8	8
125	Dengue vaccines. , 2013, , 1042-1051.		7
126	Stumbles on the path to dengue control. Lancet Infectious Diseases, The, 2014, 14, 661-662.	9.1	6

#	Article	IF	Citations
127	Dengue vaccine and the 2016 Olympics. Lancet, The, 2016, 388, 237-238.	13.7	6
128	NS1, Dengueâ€™s Dagger. Journal of Infectious Diseases, 2020, 221, 857-860.	4.0	6
129	Consultation on dengue vaccines: Progress in understanding protection, 26â€“28 June 2013, Rockville, Maryland. Vaccine, 2014, 32, 3115-3121.	3.8	5
130	Predictors of dengue severity. Jornal De Pediatria, 2016, 92, 429-431.	2.0	4
131	Cause of Primary Bladder Stone in England â€" A Retrospective Epidemiological Study. , 1981, , 325-328.		4
132	Dengue vaccines. , 2008, , 1155-1161.		4
133	Dengue Fever and Dengue Hemorrhagic Fever. , 2011, , 1147-1150.e1.		4
134	Comment on â€œDengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrityâ€•and â€œDengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccinationâ€• Science Translational Medicine, 2015, 7, 318le4.	12.4	3
135	Response to Hadinegoro et al.. Vaccine, 2016, 34, 4275.	3.8	3
136	Cause and consequence of loss in vaccine trust. Human Vaccines and Immunotherapeutics, 2019, 15, 628-629.	3.3	3
137	Three commentaries on â€˜Corticosteroids for treating dengue shock syndromeâ€™, with introduction by EBCH editor. Evidence-Based Child Health: A Cochrane Review Journal, 2007, 2, 1080-1086.	2.0	2
138	Pathogenic Exploitation of Fc Activity. , 2014, , 333-350.		2
139	Dengue Vaccines. , 2018, , 241-251.e6.		2
140	Japanese Encephalitis. , 2010, , 317-333.		2
141	Is discussion of dengue vaccination for the 2016 Olympics necessary?: Authors' reply. Lancet, The, 2016, 388, 1881-1882.	13.7	1
142	Predictors of dengue severity. Jornal De Pediatria (VersÃ£o Em PortuguÃªs), 2016, 92, 429-431.	0.2	0
143	A Step in the Right Direction. Journal of Infectious Diseases, 2020, 222, 712-714.	4.0	0
144	Nguyen Trong Lan, MD, PhD. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1117-1117.	1.4	0